Influences of the Diffusion of Psychotropic Medications

描述（由申请人提供）：本申请寻求职业发展奖，用于制药机构和政策，精神病临床决策和精神药理学的培训，以告知精神药物的经济研究。该奖项包括3项研究，旨在描述新的精神药物在一系列保险环境中的扩散，包括管理和非管理护理，全国和几个当地市场，以了解新制药技术采用和扩散率的抑制剂和促进剂。本申请的具体研究目的是：1）描述治疗行为健康障碍的主要新药的主要总体扩散模式，2）确定市场特征和精神药物产品及其竞争对手的特征是否影响药物在市场上的扩散（总体）水平，以及3）在个体水平上开发和测试药物扩散的行为模型。培训和研究活动将使候选人能够从制药行业，制药推广工作和临床文献中综合当前的研究和机构知识，并从经济学学科的理论框架中开始一条重要的调查线，目前的精神卫生服务研究文献中基本缺失。已选出四名在对该项目至关重要的领域具有专门知识的导师。戴尔克里斯滕森博士，教授和系主任。药学政策和评估科学的研究员将作为主要的导师，提供有关制药政策和营销的指导。麻省理工学院经济学教授恩斯特·伯恩特博士、哈佛教授理查德·弗兰克博士和杜克精神病学和行为科学教授马文·斯沃茨博士将担任额外的研究顾问。新的行为健康技术的传播非常不均衡。一些精神药物扩散得非常快，而另一些则没有取得很大的成功，开发了可观的市场份额。为了推进最佳做法模式，必须了解这些不同传播速度背后的因素。制药政策和相关临床背景方面的培训将使研究人员能够制定长期研究计划，以研究鼓励或阻碍获得重要新技术的因素。

DESCRIPTION (provided by applicant): This application seeks a career development award for training in pharmaceutical institutions and policies, psychiatric clinical decision-making and psychopharmacology in order to inform economic research on psychotropic medications. The award period includes 3 research aims to characterize the diffusion of new psychotropic medications across a range of insurance settings, both managed and non-managed care, nationally and in several local markets in an effort to understand the inhibitors and promoters of the adoption and diffusion rate of new pharmaceutical technologies. The specific research aims of this application are 1) to describe major aggregate patterns of diffusion of principal new drugs for the treatment of behavioral health disorders, 2) to determine whether market characteristics and characteristics of psychotropic drug products and their competitors influence the diffusion of drugs at the market (aggregate) level, and 3) to develop and test behavioral models of drug diffusion at the individual level. The training and research activities will enable the candidate to synthesize current research and institutional knowledge from the pharmaceutical industry, pharmaceutical promotion efforts, and clinical literature with a theoretical framework from the discipline of economics in order to begin an important line of inquiry largely missing from the current mental health services research literature. Four mentors with expertise in areas critical to this project have been selected. Dr. Dale Christensen, professor and chair of the Dept. of Pharmaceutical Policy and Evaluative Sciences at UNC will serve as the primary mentor, providing guidance on pharmaceutical policy and marketing. Dr. Ernst Berndt, Professor of Economics at MIT, Dr. Richard Frank, Professor at Harvard and Dr. Marvin Swartz, professor of Psychiatry and Behavioral Sciences at Duke will serve as additional research advisors. The diffusion of new behavioral health technologies has been very uneven. Some psychotropic medications have diffused very quickly while others have not had much success developing a substantial market share. In order to advance models of best practice, it is important to understand the factors that underlie these varying rates of diffusion. Training in the area of pharmaceutical policy and the relevant clinical context will allow the investigator to develop a long-term research plan to study the factors that encourage or impede access to important new technologies.